Tapestry Presents Data Supporting the Oral Bioavailability and Antitumor Activity of TPI 287
News Apr 10, 2006
Data presented indicates that TPI 287 is orally bioavailable in rats and that oral dosing of TPI 287 has antitumor activity in a mouse xenograft model.
In addition, data were presented from in vitro transport assays which demonstrate that TPI 287 is not a substrate for drug efflux in the MDCKII-MDR monolayer system and that TPI 287 demonstrates increased potency in cell cytotoxicity assays with MDR 1+ and mutant tubulin expressing tumor cell lines when compared to paclitaxel.
A poster entitled "Oral Bioavailability and antitumor activity of TPI 287 - a new taxane analog with greater activity against tumor cells with demonstrated mutant tubulin," Abstract No. 493, by David L. Emerson, Carol Bell, Mark Jones, Barbara Schiemann and Gilles Tapolsky was presented Sunday, April 2, 2006 at 8:00 AM.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018